Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 412

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 16I
Chunk 412
---
 long-term value creation in cell therapy in oncology. This is anticipated to lead to a reduction of approximately300positions across the organization in Europe, representing40% of our employees. This reorganization would result in meaningful reductions in staff in Belgium and the closure of the site in France. We would continue to operate from our main hubs in Princeton and Pittsburgh in the United States, and from Leiden, Netherlands, and Mechelen, Belgium. At the time of this annual report, the estimated restructuring costs for the restructured staff amount to €57 million.

F-72

Table of Contents

Further quantitative impacts resulting from the transaction, including total transaction costs, will be disclosed in future reporting periods when those impacts will be known.

We will provide transitional services to SpinCo on a cost-plus basis during a reasonable period after the separation to facilitate SpinCo's operations and allow it to operate on a stand-alone basis as soon as reasonably possible.

F-73

Table of Contents

EXHIBIT INDEX

                                                                                                                                                                    Incorporated by Reference                                                  
                                                                                                                                                                    Schedule/                                                    File Date     
  Exhibit      Description                                                                                                                                          Form                           File Number      Exhibit      (mm/dd/yyyy)  
  1.1#         Articles of Association April 30, 2024 (English translation)                                                                                                                                                                    
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  2.1          Form of Deposit Agreement                                                                                                                            Form F-1/A                     333-203435           4.1      04/30/2015    
  2.2          Form of American Depositary Receipt                                                                                                                  424(b)3                        333-203584             A      10/15/2018    
  2.3#         Description of Securities                                                                                                                                                                                                       
  4.1          Lease dated June 30, 1999 between the registrant and Innotech N. V., as amended (English translation)                                                Form F-1                       333-203435          10.1      04/15/2015    
  4.2†         Warrant Plans (English translation)                                                                                                                  Form F-1/A                     333-203435          10.3      05/11/2015    
  4.6##        Sale & Purchase Agreement dated March 13, 2014 between the registrant and Charles River Laboratories Holding Limited, as amended                     Form